Fig. 2

The co-expression of FAK and ROS1 was associated with the poorest prognosis, whereas the simultaneous inhibition of FAK and ROS1 suppressed cell growth synergistically. A, B The mRNA expression levels of FAK (PTK2) and ROS1 in breast cancer tissues and normal breast tissues were analyzed by the TIMER database. C, D Survival curves of OS in breast cancer patients from GSE159956 and GSE10885. E Correlation analysis of FAK and ROS1. F, G The cell viability of MDA-MB-231 cells treated with serial doses of IN10018 and crizotinib. H, I The cell viability of Hs578T cells treated with serial doses of IN10018 and crizotinib. J, K Survival curves of MDA-MB-231 and Hs578T cells treated with IN10018, crizotinib, or combination therapy. L, M The CI value of MDA-MB-231 and Hs578T cells treated with IN10018, crizotinib, or combination therapy. Data are represented as mean ± SEM. Significant levels: ns = not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001. L: Low, H: High